Hospira Recalls One Lot of Sodium Chloride Injection Due to Particulate Matter

February 4, 2015

Hospira, Inc, of Lake Forest, IL, has announced a voluntary nationwide recall of one lot of 0.9% Sodium Chloride Injection, USP, 250 mL (NDC 0409-7983-02, expiration August 1) due to the presence of particulate matter.

Hospira, Inc, of Lake Forest, IL, has announced a voluntary nationwide recall of one lot of 0.9% Sodium Chloride Injection, USP, 250 mL (NDC 0409-7983-02, expiration August 1) due to the presence of particulate matter. Hospira identified the particulate matter as a human hair, sealed in the bag at the additive port area. To date, Hospira has received no reports of adverse events associated with the recall, according to a

Safety Alert

posted to the FDA website. The affected lot, 44-002-JT, was distributed nationwide from September 2014 through November 2014. Hospira advises health care providers to stop use and distribution of the product and quarantine it immediately. The company has notified its direct distributors via a recall letter and is arranging for impacted product to be returned. Adverse reactions may be reported to FDA’s

MedWatch

Safety Information and Adverse Event Reporting Program.